CH680983C9 - - Google Patents

Download PDF

Info

Publication number
CH680983C9
CH680983C9 CH2906/90A CH290690A CH680983C9 CH 680983 C9 CH680983 C9 CH 680983C9 CH 2906/90 A CH2906/90 A CH 2906/90A CH 290690 A CH290690 A CH 290690A CH 680983 C9 CH680983 C9 CH 680983C9
Authority
CH
Switzerland
Application number
CH2906/90A
Other languages
German (de)
Other versions
CH680983A5 (en:Method
CH680983C1 (en:Method
Inventor
James Barry Douglas Palmer
Original Assignee
Glaxo Group Ltd Glaxo Wellcome
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27264677&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CH680983(C9) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB898920392A external-priority patent/GB8920392D0/en
Priority claimed from GB898923644A external-priority patent/GB8923644D0/en
Application filed by Glaxo Group Ltd Glaxo Wellcome filed Critical Glaxo Group Ltd Glaxo Wellcome
Publication of CH680983A5 publication Critical patent/CH680983A5/fr
Publication of CH680983C1 publication Critical patent/CH680983C1/xx
Publication of CH680983C9 publication Critical patent/CH680983C9/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
CH2906/90A 1989-09-08 1990-09-07 CH680983C9 (en:Method)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB898920392A GB8920392D0 (en) 1989-09-08 1989-09-08 Medicaments
GB898923644A GB8923644D0 (en) 1989-10-20 1989-10-20 Medicaments
SG166294A SG166294G (en) 1989-09-08 1994-11-18 Inhalation medicaments for treating respiratory disorders

Publications (3)

Publication Number Publication Date
CH680983A5 CH680983A5 (en:Method) 1992-12-31
CH680983C1 CH680983C1 (en:Method) 2008-06-25
CH680983C9 true CH680983C9 (en:Method) 2008-08-15

Family

ID=27264677

Family Applications (1)

Application Number Title Priority Date Filing Date
CH2906/90A CH680983C9 (en:Method) 1989-09-08 1990-09-07

Country Status (20)

Country Link
EP (1) EP0416951B1 (en:Method)
JP (1) JP3042867B2 (en:Method)
AT (1) ATE99941T1 (en:Method)
BE (1) BE1003053A3 (en:Method)
CA (1) CA2024916C (en:Method)
CH (1) CH680983C9 (en:Method)
DE (2) DE19975040I2 (en:Method)
DK (1) DK0416951T3 (en:Method)
ES (1) ES2062392T3 (en:Method)
FR (1) FR2651677B1 (en:Method)
HK (1) HK18695A (en:Method)
HU (1) HU211272A9 (en:Method)
IE (1) IE65535B1 (en:Method)
IL (1) IL95590A (en:Method)
IT (1) IT1241996B (en:Method)
LU (1) LU90392I2 (en:Method)
NL (1) NL990012I2 (en:Method)
NZ (1) NZ235221A (en:Method)
PH (1) PH27594A (en:Method)
SG (1) SG166294G (en:Method)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270305A (en) 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Surfactant-free pharmaceutical aerosol formulation comprising 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoro-n- propane as propellant
CZ288032B6 (cs) * 1991-12-18 2001-04-11 Aktiebolaget Astra Farmaceutický prostředek pro podání inhalací
SE9703407D0 (sv) 1997-09-19 1997-09-19 Astra Ab New use
SE9802073D0 (sv) 1998-06-11 1998-06-11 Astra Ab New use
CN1150895C (zh) 1998-11-13 2004-05-26 杰格研究股份公司 用于吸入给药的干粉
GB9903759D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9904919D0 (en) 1999-03-03 1999-04-28 Novartis Ag Organic compounds
CA2317999C (en) 1999-09-11 2004-11-09 Glaxo Group Limited Pharmaceutical formulation of fluticasone propionate
EP1248597B1 (en) * 1999-12-24 2005-03-30 Glaxo Group Limited Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate
GB0019172D0 (en) 2000-08-05 2000-09-27 Glaxo Group Ltd Novel compounds
PT2348032E (pt) 2000-08-05 2015-10-14 Glaxo Group Ltd Éster s-fluorometílico do ácido 6.alfa.,9.alfa.-difluoro- 17.alfa.-'(2-furanilcarboxil)oxi]-11.beta.-hidroxi-16.alfa.- metil-3-oxo-androsta-1,4-dieno-17-carbotióico como um agente anti-inflamatório
US6858593B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6777400B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6750210B2 (en) 2000-08-05 2004-06-15 Smithkline Beecham Corporation Formulation containing novel anti-inflammatory androstane derivative
US6858596B2 (en) 2000-08-05 2005-02-22 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivative
US6759398B2 (en) * 2000-08-05 2004-07-06 Smithkline Beecham Corporation Anti-inflammatory androstane derivative
US6777399B2 (en) 2000-08-05 2004-08-17 Smithkline Beecham Corporation Anti-inflammatory androstane derivative compositions
US6787532B2 (en) 2000-08-05 2004-09-07 Smithkline Beecham Corporation Formulation containing anti-inflammatory androstane derivatives
FI20002215A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
FI20002216A0 (fi) 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
JP2004526720A (ja) 2001-03-08 2004-09-02 グラクソ グループ リミテッド βアドレナリン受容体のアゴニスト
EP1370521B1 (en) 2001-03-22 2007-12-19 Glaxo Group Limited Formanilide derivatives as beta2-adrenoreceptor agonists
UA77656C2 (en) 2001-04-07 2007-01-15 Glaxo Group Ltd S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
CA2445839A1 (en) 2001-04-30 2002-11-07 Glaxo Group Limited Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
AU2002326026B2 (en) 2001-09-14 2005-04-28 Glaxo Group Limited Phenethanolamine derivatives for treatment of respiratory diseases
US7258118B2 (en) 2002-01-24 2007-08-21 Sofotec Gmbh & Co, Kg Pharmaceutical powder cartridge, and inhaler equipped with same
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
EP1757281A3 (en) * 2002-02-04 2009-07-15 Glaxo Group Limited Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
EP1471895B2 (en) 2002-02-04 2012-03-14 Glaxo Group Limited Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
AU2003221482A1 (en) * 2002-03-04 2003-09-16 Boehringer Ingelheim Pharma Gmbh And Co. Kg Novel cinnamate salts, method for production and use thereof as medicaments
GB0208609D0 (en) * 2002-04-13 2002-05-22 Glaxo Group Ltd Compositions
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
US7879833B2 (en) 2002-12-12 2011-02-01 Nycomed Gmbh Combination medicament
GB0303396D0 (en) 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds
SE527069C2 (sv) 2003-06-19 2005-12-13 Mederio Ag Förfarande och anordning för administrering av läkemedelspulver
WO2005013963A1 (en) 2003-08-06 2005-02-17 Galephar M/F Advantageous combinations for inhalation of nacystelyn and bronchodilators
JP2007528889A (ja) * 2004-03-12 2007-10-18 シプラ・リミテッド 吸入製剤
DE602005023690D1 (de) 2004-07-16 2010-11-04 Almirall Sa Inhalator für die Abgabe von pharmzeutischen Pulver, und ein Pulverkassette zur Verwendung mit diesem Inhalator
SI2063940T1 (sl) 2006-12-22 2012-05-31 Almirall Sa Inhalacijska naprava za zdravila v praškasti obliki
CN101744792B (zh) * 2008-12-17 2013-04-17 张凯 氟替卡松丙酸酯和沙美特罗昔萘酸酯复方干粉吸入剂及其制备工艺
PL3111926T3 (pl) 2009-05-29 2020-06-29 Pearl Therapeutics, Inc. Kompozycje, sposoby i układy do dostarczania dwóch lub większej liczby środków czynnych do układu oddechowego
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
CA2905542C (en) 2013-03-15 2022-05-03 Pearl Therapeutics, Inc. Methods and systems for conditioning of particulate crystalline materials
US20160158149A1 (en) * 2013-04-29 2016-06-09 Sanofi Sa Inhalable Pharmaceutical Compositions and the Inhaler Devices Containing Them

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2107715B (en) * 1981-10-19 1985-11-13 Glaxo Group Ltd Micronised beclomethasone dipropionate monohydrate and powder inhalation compositions containing it
ZW6584A1 (en) * 1983-04-18 1985-04-17 Glaxo Group Ltd Phenethanolamine derivatives
FR2588474B1 (fr) * 1985-10-16 1987-11-27 Cird Compositions synergetiques anti-inflammatoires a base d'un corticosteroide et d'un beta agoniste

Also Published As

Publication number Publication date
IL95590A (en) 1996-06-18
JPH03167120A (ja) 1991-07-19
ATE99941T1 (de) 1994-01-15
FR2651677B1 (fr) 1993-08-06
IE903256A1 (en) 1991-03-13
DK0416951T3 (da) 1994-02-14
PH27594A (en) 1993-08-31
CH680983A5 (en:Method) 1992-12-31
EP0416951B1 (en) 1994-01-12
IT1241996B (it) 1994-02-02
SG166294G (en) 1995-06-16
HU211272A9 (en) 1995-11-28
EP0416951A1 (en) 1991-03-13
HK18695A (en) 1995-02-17
IL95590A0 (en) 1991-09-16
FR2651677A1 (fr) 1991-03-15
CH680983C1 (en:Method) 2008-06-25
IT9048260A0 (it) 1990-09-07
JP3042867B2 (ja) 2000-05-22
ES2062392T3 (es) 1994-12-16
IT9048260A1 (it) 1992-03-07
DE19975040I2 (de) 2006-07-13
LU90392I2 (fr) 1999-06-28
NZ235221A (en) 1992-11-25
CA2024916A1 (en) 1991-03-09
IE65535B1 (en) 1995-11-01
DE69005951T2 (de) 1994-05-26
NL990012I1 (nl) 1999-07-01
BE1003053A3 (fr) 1991-11-05
CA2024916C (en) 2002-07-09
NL990012I2 (nl) 1999-09-01
DE69005951D1 (de) 1994-02-24

Similar Documents

Publication Publication Date Title
DK0407615T3 (en:Method)
DK0479920T3 (en:Method)
FR2642301B1 (en:Method)
EP0679974A3 (en:Method)
DE4193486T1 (en:Method)
CH680983C9 (en:Method)
GR3006855T3 (en:Method)
FR2641544B1 (en:Method)
FR2642692B1 (en:Method)
FR2641915B1 (en:Method)
FR2656386B1 (en:Method)
FR2641888B3 (en:Method)
FR2641583B1 (en:Method)
DE3991748T1 (en:Method)
FR2642612B1 (en:Method)
AU638668B2 (en:Method)
GR2000820Y (en:Method)
IN172711B (en:Method)
IN173891B (en:Method)
GR2000294Y (en:Method)
IN173741B (en:Method)
DK107689D0 (en:Method)
AU2141188A (en:Method)
DK393789D0 (en:Method)
IN171181B (en:Method)

Legal Events

Date Code Title Description
SPCF Supplementary protection certificate filed

Free format text: OICM-NO 54975/19990329, 19990602

SPCG Supplementary protection certificate granted

Free format text: OICM-NO 54975/19990329, 19990602, EXPIRES:20140329

SPCN Certificates - modification new representative

Spc suppl protection certif: C680983/01

Representative=s name: BRAUNPAT BRAUN EDER AG, CH

NV New agent
PFA Name/firm changed

Owner name: GLAXO GROUP LIMITED

Free format text: GLAXO GROUP LIMITED#6-12 CLARGES STREET#LONDON W1Y 8DH (GB) $ ISLER & PEDRAZZINI AG#POSTFACH 1772#8027 ZUERICH (CH) -TRANSFER TO- GLAXO GROUP LIMITED#GLAXO WELLCOME HOUSE, BERKELEY AVENUE#GREENFORD (MIDDX UB6 0NN) (GB) $ ISLER & PEDRAZZINI AG#POSTFACH 1772#8027 ZUERICH (CH)

PK Correction

Free format text: LE MANDATAIRE A ETE MENTIONNE PAR ERREUR COMME TITULAIRE.

AEN Scope or validity of the patent modified

Free format text: DECLARATION DE RENONCIATION PUBLIEE: 25.06.2008

PK Correction

Free format text: INHABER + VERTRETER KORRIGIERT.

PL Patent ceased
SPCP Certificates - modification of firm

Owner name: GLAXO GROUP LIMITED, GB

Spc suppl protection certif: C680983/01

SPCL Supplementary protection certificate deletion

Spc suppl protection certif: C680983/01